Literature DB >> 29932949

miRNA-221 and miRNA-222 are promising biomarkers for progression of liver fibrosis in HCV Egyptian patients.

Amanda Abdel-Al1, Eman El-Ahwany2, Mona Zoheiry2, Marwa Hassan3, Amged Ouf1, Hoda Abu-Taleb4, Ali Abdel Rahim5, Mohamed Darwish El-Talkawy5, Suher Zada1.   

Abstract

BACKGROUND: Current methodologies used to determine the progression of hepatic fibrosis rely heavily on liver biopsy, a dangerous and invasive procedure, with semi-subjective analysis of the results of the biopsy. Thus, a new approach is immensely needed for monitoring the progression of liver fibrosis in Hepatitis C virus (HCV) patients. AIM OF WORK: The purpose of this study was to find highly specific and sensitive miRNA biomarkers that can be used to detect different stages of liver fibrosis.
METHODOLOGY: The study consisted of 42 cases of chronic hepatitis C (CHC) with early-stage fibrosis, 45 cases of CHC with late-stage fibrosis, and 40 healthy subjects with no CHC or fibrosis as controls. Expression patterns of 5 miRNAs (miR-16, miR-146a, miR-214-5p, miR-221, and miR-222) were analyzed in each group using TaqMan real-time PCR.
RESULTS: Serum levels of miRNA-16, miRNA-146a, miRNA-221, and miRNA-222 were all significantly up-regulated in early and late stages of liver fibrosis. miRNA-222 had the highest sensitivity and specificity values in early and late fibrosis. miRNA-221 had the second highest sensitivity and specificity with the late-stage fibrosis group. Furthermore, miRNA-221 showed significant positive correlations with both miRNA-16 and miRNA-146a in the early- and late-stage fibrosis groups, with the early stage having a stronger correlation.
CONCLUSIONS: The results indicated that miRNA-16, miRNA-146a, miRNA-221, and miRNA-222 can be used to detect the presence of liver fibrosis. The high sensitivity and specificity of miRNA-222 and miRNA-221 in late-stage fibrosis indicate promising prognostic biomarkers for HCV-induced liver fibrosis.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarkers; HCV; Liver fibrosis; miRNAs

Mesh:

Substances:

Year:  2018        PMID: 29932949     DOI: 10.1016/j.virusres.2018.06.007

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  11 in total

1.  Novel inhibitors against wild-type and mutated HCV NS3 serine protease: an in silico study.

Authors:  Ahmed A Ezat; Abdo A Elfiky; Wael M Elshemey; Noha A Saleh
Journal:  Virusdisease       Date:  2019-03-21

2.  The Dynamic Interplay Between Mast Cells, Aging/Cellular Senescence, and Liver Disease.

Authors:  Debjyoti Kundu; Lindsey Kennedy; Vik Meadows; Leonardo Baiocchi; Gianfranco Alpini; Heather Francis
Journal:  Gene Expr       Date:  2020-07-29

3.  miR-491-5p inhibits Emilin 1 to promote fibroblasts proliferation and fibrosis in gluteal muscle contracture via TGF-Beta1/Smad2 pathway.

Authors:  Shuai Chen; Qiuwan Wu; Yang Wang; Jie Xu; Ye Wang; Xianyang Luo
Journal:  Physiol Res       Date:  2022-04-11       Impact factor: 2.139

Review 4.  Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis.

Authors:  Mousumi Khatun; Ratna B Ray
Journal:  Cells       Date:  2019-10-14       Impact factor: 6.600

Review 5.  Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma-A Review.

Authors:  Kyoko Oura; Asahiro Morishita; Tsutomu Masaki
Journal:  Int J Mol Sci       Date:  2020-11-07       Impact factor: 5.923

6.  Effects of free and nanoparticulate curcumin on chemically induced liver carcinoma in an animal model.

Authors:  Eman Shawky Mohammed; Nadia M El-Beih; Enas Ali El-Hussieny; Eman El-Ahwany; Marwa Hassan; Mona Zoheiry
Journal:  Arch Med Sci       Date:  2020-03-17       Impact factor: 3.318

7.  The Diagnosis Value of a Novel Model with 5 Circulating miRNAs for Liver Fibrosis in Patients with Chronic Hepatitis B.

Authors:  Qingqing Zhang; Qidi Zhang; Binghang Li; Ying Qu; Zhenghong Li; Lungen Lu; Rongzhou Li; Xiaobo Cai
Journal:  Mediators Inflamm       Date:  2021-03-01       Impact factor: 4.711

8.  Long non‑coding RNA MBI‑52 inhibits the development of liver fibrosis by regulating the microRNA‑466g/SMAD4 signaling pathway.

Authors:  Yazhou Li; Peixiao Liu; Feipeng Wei
Journal:  Mol Med Rep       Date:  2021-12-01       Impact factor: 2.952

9.  The Long Noncoding RNA LINC00963 Inhibits Corneal Fibrosis Scar Formation by Targeting miR-143-3p.

Authors:  Lixia Zhang; Jinning Gao; Anjing Gong; Yanhan Dong; Xiaodan Hao; Xuekang Wang; Jian Zheng; Wenmeng Ma; Yiying Song; Jie Zhang; Wenhua Xu
Journal:  DNA Cell Biol       Date:  2022-03-08       Impact factor: 3.550

10.  MicroRNA-708 modulates Hepatic Stellate Cells activation and enhances extracellular matrix accumulation via direct targeting TMEM88.

Authors:  Tao Xu; Linxin Pan; Liangyun Li; Shuang Hu; Hong Zhou; Chenchen Yang; Junfa Yang; Haodong Li; Yuming Liu; Xiaoming Meng; Jun Li
Journal:  J Cell Mol Med       Date:  2020-05-28       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.